Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters








Publication year range
1.
ACS Infect Dis ; 10(6): 1871-1889, 2024 Jun 14.
Article in English | MEDLINE | ID: mdl-38829047

ABSTRACT

Leishmaniasis, one of the most overlooked tropical diseases, is a life-threatening illness caused by the parasite Leishmania donovani that is prevalent in underdeveloped nations. Over 350 million individuals in more than 90 different nations worldwide are at risk of contracting the disease, which has a current fatality rate of 50 000 mortalities each year. The administration of liposomal Amp B, pentavalent antimonials, and miltefosine are still considered integral components of the chemotherapy regimen. Antileishmanial medications fail to treat leishmaniasis because of their numerous drawbacks. These include inadequate effectiveness, toxicity, undesired side effects, drug resistance, treatment duration, and cost. Consequently, there is a need to overcome the limitations of conventional therapeutics. Nanotechnology has demonstrated promising outcomes in addressing these issues because of its small size and distinctive characteristics, such as enhanced bioavailability, lower toxicity, biodegradability, and targeted drug delivery. This review is an effort to highlight the recent progress in various nanodrug delivery systems (nDDSs) over the past five years for treating leishmaniasis. Although the preclinical outcomes of nDDSs have shown promising treatment for leishmaniasis, further research is needed for their clinical translation. Advancement in three primary priority domains─molecular diagnostics, clinical investigation, and knowledge dissemination and standardization─is imperative to propel the leishmaniasis field toward translational outcomes.


Subject(s)
Antiprotozoal Agents , Drug Delivery Systems , Leishmaniasis , Humans , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Leishmaniasis/drug therapy , Drug Delivery Systems/methods , Animals , Nanoparticles , Leishmania donovani/drug effects , Leishmaniasis Vaccines/administration & dosage , Nanovaccines
2.
Int J Pharm ; 648: 123579, 2023 Dec 15.
Article in English | MEDLINE | ID: mdl-37931727

ABSTRACT

The research work aimed to develop a robust sustained release biocompatible brinzolamide (BRZ)-loaded ocular inserts (MeltSerts) using hot-melt extrusion technology with enhanced solubility for glaucoma management. A 32 rotatable central composite design was employed for the optimization of the MeltSerts to achieve sustained release. The effect of two independent factors was examined: Metolose® SR 90SH-100000SR (HPMC, hydroxypropyl methyl cellulose) and Kolliphor® P 407 (Poloxamer 407, P407). The drug release (DR) of BRZ at 0.5 h and 8 h were adopted as dependent responses. The factorial analysis resulted in an optimum composition of 50.00 % w/w of HPMC and 15.00 % w/w of P407 which gave % DR of 9.11 at 0.5 h and 69.10 at 8 h. Furthermore, molecular dynamic simulations were performed to elucidate various interactions between BRZ, and other formulation components and it was observed that BRZ showed maximum interactions with HPC and HPMC with an occupancy of 92.82 and 52.87 %, respectively. Additionally, molecular docking studies were performed to understand the interactions between BRZ and mucoadhesive polymers with ocular mucin (MUC-1). The results indicated a docking score of only -5.368 for BRZ alone, whereas a significantly higher docking score was observed for the optimized Meltserts -6.977, suggesting enhanced retention time of the optimized MeltSerts. SEM images displayed irregular surfaces, while EDS analysis validated uniform BRZ distribution in the optimized formulation. The results of the ocular irritancy studies both ex vivo and in vivo demonstrated that MeltSerts are safe for ocular use. The results indicate that the developed MeltSerts Technology has the potential to manufacture ocular inserts with cost-effectiveness, one-step processability, and enhanced product quality. Nonetheless, it also offers a once-daily regimen, consequently decreasing the dosing frequency, preservative exposure, and ultimately better glaucoma management.


Subject(s)
Glaucoma , Molecular Dynamics Simulation , Humans , Delayed-Action Preparations/therapeutic use , Molecular Docking Simulation , Glaucoma/drug therapy , Solubility , Technology
3.
Plants (Basel) ; 12(14)2023 Jul 12.
Article in English | MEDLINE | ID: mdl-37514241

ABSTRACT

Four species of the genus Hedychium can be found in Brazil. Hedychium coronarium is a species endemic to India and Brazil. In this paper, we collected six specimens of H. coronarium for evaluation of their volatile chemical profiles. For this, the essential oils of these specimens were extracted using hydrodistillation from plant samples collected in the state of Pará, Brazil, belonging to the Amazon region in the north of the country. Substance compounds were identified with GC/MS. The most abundant constituent identified in the rhizome and root oils was 1,8-cineole (rhizome: 35.0-66.1%; root: 19.6-20.8%). Leaf blade oil was rich in ß-pinene (31.6%) and (E)-caryophyllene (31.6%). The results from this paper allow for greater knowledge about the volatile chemical profile of H. coronarium specimens, in addition to disseminating knowledge about the volatile compounds present in plant species in the Amazon region.

4.
Future Med Chem ; 15(7): 579-582, 2023 04.
Article in English | MEDLINE | ID: mdl-37140141

ABSTRACT

Organoids provide us an opportunity to understand how diseases affect cellular physiology, human tissues or organs. They are indespensible tools for biomaterial toxicity analysis, drug discovery and regenerative medicine.


Subject(s)
Biocompatible Materials , Organoids , Humans , Biocompatible Materials/toxicity , Regenerative Medicine , Drug Discovery
5.
Eur J Pharm Biopharm ; 188: 108-124, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37182553

ABSTRACT

In situ gelling systems (ISGS) can prolong retention time and bioavailability of ophthalmic solutions. The complexity and cost of ISGS avert their industrial scale-up and clinical implementation. In this study, we demonstrate novel application of hot-melt extrusion (HME) technology for continuous manufacturing of ISGS (MeltDrops Technology). Timolol maleate (TIM) and dorzolamide hydrochloride (DRZ) loaded MeltDrops were successfully developed using HME for glaucoma management, thereby resolving issues with batch manufacturing of ISGS, prolonging retention time thus improving bioavailability. The MeltDrops technology involves one-step, i.e., passing all the ingredients through an extruder at a screw speed between 20 and 50 rpm and barrel temperature of 80 °C. The comparative evaluation of MeltDrops and batch-processed ISGS demonstrated that MeltDrops exhibited better physical and chemical content uniformity. The extrusion temperature and screw speed were critical factors influencing content uniformity and properties of the MeltDrops. MeltDrops showed sustained drug release for > 12 h in vitro (TIM = 83.07%; DRZ = 60.43%, 12 h) versus marketed eyedrops. The developed MeltDrops followed Peppas-Sahlin model, combining Fickian diffusion and swelling processes. The in vivo study in New Zealand rabbits revealed superior effectiveness and safety of the MeltDrops as compared to the marketed eyedrops. Herein we conclude, MeltDrops would serve as a cutting-edge platform technology that can be used to manufacture various ISGS with one-step processability, cost-effectiveness, and improved product quality, which are otherwise processed by batch manufacturing that involves numerous complex processing steps.


Subject(s)
Hot Melt Extrusion Technology , Technology, Pharmaceutical , Animals , Rabbits , Biological Availability , Drug Liberation , Hot Temperature , Computer Simulation , Drug Compounding
7.
Pharmaceuticals (Basel) ; 16(4)2023 Apr 18.
Article in English | MEDLINE | ID: mdl-37111369

ABSTRACT

Calendula officinalis Linn. (CO) is a popular medicinal plant from the plant kingdom's Asteraceae family that has been used for millennia. This plant contains flavonoids, triterpenoids, glycosides, saponins, carotenoids, volatile oil, amino acids, steroids, sterols, and quinines. These chemical constituents confer multifaceted biological effects such as anti-inflammatory, anti-cancer, antihelminthic, antidiabetes, wound healing, hepatoprotective, and antioxidant activities. Additionally, it is employed in cases of certain burns and gastrointestinal, gynecological, ocular, and skin conditions. In this review, we have discussed recent research from the last five years on the therapeutic applications of CO and emphasized its myriad capabilities as a traditional medicine. We have also elucidated CO's molecular mechanisms and recent clinical studies. Overall, this review intends to summarize, fill in the gaps in the existing research, and provide a wealth of possibilities for researchers working to validate traditional claims and advance the safe and effective use of CO in treating various ailments.

8.
ACS Omega ; 8(13): 11674-11699, 2023 Apr 04.
Article in English | MEDLINE | ID: mdl-37033812

ABSTRACT

Surfactants are a group of amphiphilic molecules (i.e., having both hydrophobic and hydrophilic domains) that are a vital part of nearly every contemporary industrial process such as in agriculture, medicine, personal care, food, and petroleum. In general surfactants can be derived from (i) petroleum-based sources or (ii) microbial/plant origins. Petroleum-based surfactants are obvious results from petroleum products, which lead to petroleum pollution and thus pose severe problems to the environment leading to various ecological damages. Thus, newer techniques have been suggested for deriving surfactant molecules and maintaining environmental sustainability. Biosurfactants are surfactants of microbial or plant origins and offer much added advantages such as high biodegradability, lesser toxicity, ease of raw material availability, and easy applicability. Thus, they are also termed "green surfactants". In this regard, this review focused on the advantages of biosurfactants over the synthetic surfactants produced from petroleum-based products along with their potential applications in different industries. We also provided their market aspects and future directions that can be considered with selections of biosurfactants. This would open up new avenues for surfactant research by overcoming the existing bottlenecks in this field.

9.
J Integr Med ; 21(3): 236-244, 2023 05.
Article in English | MEDLINE | ID: mdl-36973157

ABSTRACT

Cannabidiol (CBD), a nonpsychotropic phytocannabinoid that was once largely disregarded, is currently the subject of significant medicinal study. CBD is found in Cannabis sativa, and has a myriad of neuropharmacological impacts on the central nervous system, including the capacity to reduce neuroinflammation, protein misfolding and oxidative stress. On the other hand, it is well established that CBD generates its biological effects without exerting a large amount of intrinsic activity upon cannabinoid receptors. Because of this, CBD does not produce undesirable psychotropic effects that are typical of marijuana derivatives. Nonetheless, CBD displays the exceptional potential to become a supplementary medicine in various neurological diseases. Currently, many clinical trials are being conducted to investigate this possibility. This review focuses on the therapeutic effects of CBD in managing neurological disorders like Alzheimer's disease, Parkinson's disease and epilepsy. Overall, this review aims to build a stronger understanding of CBD and provide guidance for future fundamental scientific and clinical investigations, opening a new therapeutic window for neuroprotection. Please cite this article as: Tambe SM, Mali S, Amin PD, Oliveira M. Neuroprotective potential of Cannabidiol: Molecular mechanisms and clinical implications. J Integr Med. 2023; 21(3): 236-244.


Subject(s)
Cannabidiol , Cannabinoids , Cannabis , Epilepsy , Neuroprotective Agents , Humans , Cannabidiol/pharmacology , Cannabidiol/therapeutic use , Neuroprotection , Cannabinoids/pharmacology , Cannabinoids/therapeutic use , Epilepsy/drug therapy , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use
10.
Pharmaceutics ; 14(10)2022 Oct 16.
Article in English | MEDLINE | ID: mdl-36297638

ABSTRACT

Amorphous solid dispersions (ASDs) are among the most popular and widely studied solubility enhancement techniques. Since their inception in the early 1960s, the formulation development of ASDs has undergone tremendous progress. For instance, the method of preparing ASDs evolved from solvent-based approaches to solvent-free methods such as hot melt extrusion and Kinetisol®. The formulation approaches have advanced from employing a single polymeric carrier to multiple carriers with plasticizers to improve the stability and performance of ASDs. Major excipient manufacturers recognized the potential of ASDs and began introducing specialty excipients ideal for formulating ASDs. In addition to traditional techniques such as differential scanning calorimeter (DSC) and X-ray crystallography, recent innovations such as nano-tomography, transmission electron microscopy (TEM), atomic force microscopy (AFM), and X-ray microscopy support a better understanding of the microstructure of ASDs. The purpose of this review is to highlight the recent advancements in the field of ASDs with respect to formulation approaches, methods of preparation, and advanced characterization techniques.

11.
Nanomedicine (Lond) ; 17(23): 1779-1798, 2022 10.
Article in English | MEDLINE | ID: mdl-36636930

ABSTRACT

Lung cancer is the second leading cause of cancer-related mortality globally, and non-small-cell lung cancer accounts for most lung cancer cases. Nanotechnology-based drug-delivery systems have exhibited immense potential in lung cancer therapy due to their fascinating physicochemical characteristics, in vivo stability, bioavailability, prolonged and targeted delivery, gastrointestinal absorption and therapeutic efficiency of their numerous chemotherapeutic agents. However, traditional chemotherapeutics have systemic toxicity issues; therefore, dietary polyphenols might potentially replace them in lung cancer treatment. Polyphenol-based targeted nanotherapeutics have demonstrated interaction with a multitude of protein targets and cellular signaling pathways that affect major cellular processes. This review summarizes the various molecular mechanisms and targeted therapeutic potentials of nanoengineered dietary polyphenols in the effective management of lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Carcinoma , Lung Neoplasms , Humans , Lung Neoplasms/drug therapy , Carcinoma, Non-Small-Cell Lung/drug therapy , Polyphenols/therapeutic use , Polyphenols/chemistry , Lung , Carcinoma/drug therapy
12.
Nanomedicine (Lond) ; 17(23): 1799-1816, 2022 10.
Article in English | MEDLINE | ID: mdl-36636965

ABSTRACT

Flavonoids represent a major group of polyphenolic compounds. Their capacity to inhibit tumor proliferation, cell cycle, angiogenesis, migration and invasion is substantially responsible for their chemotherapeutic activity against lung cancer. However, their clinical application is limited due to poor aqueous solubility, low permeability and quick blood clearance, which leads to their low bioavailability. Nanoengineered systems such as liposomes, nanoparticles, micelles, dendrimers and nanotubes can considerably enhance the targeted action of the flavonoids with improved efficacy and pharmacokinetic properties, and flavonoids can be successfully translated from bench to bedside through various nanoengineering approaches. This review addresses the therapeutic potential of various flavonoids and highlights the cutting-edge progress in the nanoengineered systems that incorporate flavonoids for treating lung cancer.


Subject(s)
Lung Neoplasms , Nanoparticles , Neoplasms , Humans , Drug Delivery Systems , Polyphenols/therapeutic use , Neoplasms/drug therapy , Liposomes/therapeutic use , Lung Neoplasms/drug therapy , Flavonoids/pharmacology , Flavonoids/therapeutic use
13.
Ther Deliv ; 13(1): 31-49, 2022 01.
Article in English | MEDLINE | ID: mdl-34766509

ABSTRACT

Drug delivery via the pulmonary route is a cornerstone in the pharmaceutical sector as an alternative to oral and parenteral administration. Nebulizer inhalation treatment offers multiple drug administration, easily employed with tidal breathing, suitable for children and elderly, can be adapted for severe patients and visible spray ensures patient satisfaction. This review discusses the operational and mechanical characteristics of nebulizer delivery devices in terms of aerosol production processes, their usage, benefits and drawbacks that are currently shaping the contemporary landscape of inhaled drug delivery. With the advent of particle engineering, novel inhaled nanosystems can be successfully developed to increase lung deposition and decrease pulmonary clearance. The above-mentioned advances might pave the path for treating a life-threatening disorder like severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is also discussed in the current state of the art.


Subject(s)
COVID-19 , Drug Delivery Systems , Administration, Inhalation , Aerosols , Aged , Bronchodilator Agents , Child , Equipment Design , Humans , Lung , Nebulizers and Vaporizers , SARS-CoV-2
14.
Spectrochim Acta A Mol Biomol Spectrosc ; 255: 119682, 2021 Jul 05.
Article in English | MEDLINE | ID: mdl-33770736

ABSTRACT

Dorzolamide hydrochloride and timolol maleate is a well-established fixed-dose combination for the treatment of glaucoma worldwide. The utilization of simulated biological fluids can give a superior understanding of the release mechanisms and practicable in vivo nature of a dosage form that can improve the predictive potential of in vitro drug release testing. No method has been reported so far for the simultaneous estimation of dorzolamide and timolol in simulated tear fluid. In the present study, a simple, precise, and accurate first-order derivative ultraviolet spectrophotometric method for the routine analysis of dorzolamide and timolol in simulated tear fluid is proposed for in vitro drug release testing. The developed method was validated as per International Conference on Harmonization guidelines Q2 (R1). First-order derivative UV spectrophotometry was successfully applied to separate the overlapping peaks of dorzolamide and timolol by measuring peak amplitude at 251.80 nm and absorbance at 295.00 nm, respectively. The method was found to be accurate and precise, with a recovery range of 98.0 -101.0% and low relative standard deviations (<2.0%). The developed method was successfully applied for in vitro drug release testing of in-house in situ gel and marketed eye drops containing dorzolamide and timolol. Various mathematical models were adopted to fit the in vitro drug release profile. It was observed that the drug release of both drugs from the in situ gel and the marketed solution were best fitted by the Higuchi and first-order kinetic models, respectively. Moreover, the analysis of variance (ANOVA) provision was used for the validation of results. Overall, with the advantages of simple and fast operations, as well as reliability, the proposed method offers an ideal platform for routine analysis as compared to other high-cost and time-consuming chromatographic techniques. Having access to such a robust method will encourage the use of simulated tear fluid for in vitro drug release testing of ocular products and help to predict the in vivo performances of ophthalmic preparations.


Subject(s)
Thiophenes , Timolol , Antihypertensive Agents , Drug Combinations , Drug Liberation , Ophthalmic Solutions , Reproducibility of Results , Sulfonamides
SELECTION OF CITATIONS
SEARCH DETAIL